Phaseline

Companies › Cellbion

Cellbion: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Apr 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lutetium (177Lu) DGUL
Radioactive PSMA-targeting prostate cancer therapeutic
–Phase 1Metastatic Castration-resistant Prostate Cancer (mCRPC)Apr 2029
Ga-68-NGUL
Diagnostic radiopharmaceutical (gallium-68 labeled)
–Phase 1Prostate Cancer–
Lu-177-DGUL
Therapeutic radiopharmaceutical (lutetium-177 labeled)
–Phase 1Prostate Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05547061Lu-177-DGULPhase 1Prostate CancerOncologyJul 2025
NCT05547061Ga-68-NGULPhase 1Prostate CancerOncologyJul 2025
NCT07244393Lutetium (177Lu) DGULPhase 1Metastatic Castration-resistant Prostate Cancer (mCRPC)OncologyApr 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.